KBC Group NV raised its stake in STERIS plc (NYSE:STE) by 30.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,595 shares of the medical equipment provider’s stock after buying an additional 9,287 shares during the quarter. KBC Group NV’s holdings in STERIS were worth $7,542,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of STE. Norges Bank purchased a new stake in STERIS in the 4th quarter valued at $154,809,000. Alliancebernstein L.P. grew its holdings in STERIS by 21.3% in the 4th quarter. Alliancebernstein L.P. now owns 1,072,411 shares of the medical equipment provider’s stock valued at $203,265,000 after buying an additional 188,412 shares in the last quarter. BlackRock Inc. grew its holdings in shares of STERIS by 1.9% during the 4th quarter. BlackRock Inc. now owns 7,688,347 shares of the medical equipment provider’s stock worth $1,457,251,000 after purchasing an additional 142,327 shares during the period. Morgan Stanley grew its holdings in shares of STERIS by 84.5% during the 4th quarter. Morgan Stanley now owns 290,418 shares of the medical equipment provider’s stock worth $55,046,000 after purchasing an additional 133,016 shares during the period. Finally, WCM Investment Management LLC grew its holdings in shares of STERIS by 1.9% during the 4th quarter. WCM Investment Management LLC now owns 6,592,382 shares of the medical equipment provider’s stock worth $1,249,520,000 after purchasing an additional 123,446 shares during the period. Institutional investors own 90.01% of the company’s stock.
STE opened at $213.47 on Tuesday. The stock’s 50-day moving average price is $199.31 and its 200 day moving average price is $189.52. STERIS plc has a 12-month low of $138.66 and a 12-month high of $216.74. The company has a current ratio of 2.64, a quick ratio of 2.00 and a debt-to-equity ratio of 0.28. The firm has a market cap of $18.22 billion, a price-to-earnings ratio of 43.30 and a beta of 0.59.
A number of equities analysts have recently weighed in on the company. Raymond James reiterated a “hold” rating on shares of STERIS in a report on Wednesday, January 20th. KeyCorp increased their price target on STERIS from $224.00 to $227.00 and gave the stock an “overweight” rating in a report on Wednesday, March 17th. Zacks Investment Research cut STERIS from a “buy” rating to a “hold” rating and set a $227.00 price target for the company. in a report on Tuesday, April 27th. Finally, Robert W. Baird increased their price target on STERIS from $200.00 to $230.00 and gave the stock an “outperform” rating in a report on Wednesday, January 13th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $216.80.
In related news, VP Julia Madsen sold 1,000 shares of the stock in a transaction dated Friday, April 23rd. The stock was sold at an average price of $215.00, for a total transaction of $215,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Read More: Resistance Level
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.